Dmitry V. Mikhalishin

Dmitry V. Mikhalishin

Auto-generated profile, based on publicly available information

Dmitry V. Mikhalishin

Federal Centre for Animal Health

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Veterinary Science Today
Verified
Journal Article
Open access
PDF file
FHFederal Centre for Animal Health
Federal Centre for Animal Health
МDМ. I. Doronin
М. I. Doronin
DMD. V. Mikhalishin
D. V. Mikhalishin
ASAlexander Sprygin
Alexander Sprygin
AMAli Mazloum
Ali Mazloum
АМА. Мазлум
А. Мазлум
Currently fluorescent quantitative real-time polymerase chain reaction, which is a cutting-edge technology in genetic diagnosis, is used in different areas of molecular biology. Practical advantage of simplicity as well as combination of high speed, sensitivity and specificity made it possible to use this analysis for nucleic acid quantitation. The paper presents general information and recommended rules for the development of real-time qPCR. The publication is aimed to acquaint the researchers and reviewers with necessary requirements to be followed in order to ensure high accuracy, reliability and transparency of the experiments, correct interpretation and repeatability of the test results. Current approaches are described that allow obtaining reliable and consistent results by different operators, at different times and in different laboratories. Basic requirements for reagents used, nucleotide sequences and validation methods are given. In general, the publication gives the information needed to achieve three ultimate goals: to provide the authors with a broad range of tools and requirements for the development of real-time qPCR based-techniques; to give the possibility to the reviewers and editors of assessing the quality of articles and guidelines/instructions in accordance with the required criteria; to obtain consistent and reliable results of tests performed using this method.

1 January 2023 in Veterinary Science Today
Verified
Journal Article
Closed access
DMDmitry V. Mikhalishin
Dmitry V. Mikhalishin
VMValery V. Mikhalishin
Valery V. Mikhalishin
YGYkhlas M. Gochmuradov
Ykhlas M. Gochmuradov
YEYulia S. El'KIna
Yulia S. El'KIna

30 March 2020 in Veterinary Science Today
Verified
Journal Article
Open access
PDF file
MDM. I. Doronin
M. I. Doronin
DLD. A. Lozovoy
D. A. Lozovoy
VPV. V. Pronin
V. V. Pronin
DMD. V. Mikhalishin
D. V. Mikhalishin
VSV. A. Starikov
V. A. Starikov
ASA. A. Shishkova
A. A. Shishkova
At present, Miramistin drug (benzyldimethyl [3-(myristoylamino) propyl] ammonium chloride monohydrate), which has a broad bactericidal effect, is used in veterinary practice. This antiseptic is active against most viruses, mycoplasmas, bacteria, fungi and protozoa. According to toxicometric parameters, Miramistin is classified as a low-hazard substance. Use of cell structures as test systems for assessing the toxicity of pharmacological substances instead of conventional tests on experimental animals allows us to better clarify the possible mechanism of the effect of the investigated substance. Since many types of mycoplasmas affect the genitourinary system organs, to assess the cytotoxicity of Miramistin kidney mammalian cells of various mammals can be used as test systems, in particular, the newborn Syrian hamster (VNK-21), Siberian mountain ibex (PSGK-30), and others. The possibility of using BHK-21 and PSGK-30 cell monolayer as test systems for assessing the baseline cytotoxicity of Miramistin was shown. When studying toxicity of the drug, the effect of its various concentrations on the cell morphology was studied, the number of viable cells and the total protein content were determined as an indicator of the cell mass increase. The results of a cytomorphological study indicate that the Miramistin maximum permissible concentration of for BHK-21 and PSGK-30 cell monolayer is 25 μg/cm3. The use of this antibacterial drug in higher concentrations caused the appearance and increased signs of endogenous intoxication and degeneration. When evaluating the proliferative activity of cells under the influence of the Miramistin antibiotic in different concentrations, it was found that increasing the dose to 50, 75, 100, 125, 150 μg/cm3 leads to decrease in the rate of cell growth compared to the control. The Miramistin content in the growth medium in an amount of up to 25 μg/cm3 did not affect the intensity of protein synthesis. Presence of Miramistin in the culture medium at the maximum permissible concentration causes a slight decrease in the reproduction of foot and mouth disease virus in BHK-21 and PSGK-30 cell cultures by 4.5 and 4.0%, respectively, compared with the control without antibiotic. Since mycoplasmas are the most common contaminants of cell cultures, further studies will be aimed at exploring the possibility of using Miramistin for decontamination of BHK-21 and PSGK-30 cell monolayers.

30 March 2020 in Veterinary Science Today
Verified
Journal Article
Open access
PDF file
ASA. V. Shishkov
A. V. Shishkov
DLD. A. Lozovoy
D. A. Lozovoy
ABA. V. Borisov
A. V. Borisov
DMD. V. Mikhalishin
D. V. Mikhalishin
Rabies is one of the most important human and animal viral diseases, being one of the most dangerous zoonoses, causing damage to the central nervous system with an inevitable fatal outcome. This disease is of global concern, and it attracts special attention of international organizations (WHO, OIE, FAO, GARC) and of veterinary services in many countries around the world. A variety of anti-rabies vaccines have been used for specific rabies prevention in wild carnivores, however, the safety and effectiveness of some of them is doubtful. New, more advanced products are being developed, one of which is Ferarabivac, a live oral vaccine. The vaccine was tested for its immunogenicity and protectivity in wild carnivores. The optimal immunizing dose was 2.0 cm3, with the infectivity titre of RV-97 strain of at least 6.00 lg KKID50/cm3. Anti-rabies antibody titres detected in the blood sera of foxes and raccoon dogs 14 days post vaccination, were 0.70 ± 0.18 and 0.73 ± 0.19 IU/cm3, respectively, which provided protection against rabies virus infection (≥ 0.50 IU/cm3). Rabies virus neutralizing antibodies in foxes reached their maximum level of 4.30 ± 0.32 IU/cm3 50 days post vaccination. Antibody titres in vaccinated raccoon dogs also reached their maximum level of 4.53 ± 0.27 IU/cm3 50 days post vaccination. The minimum protective threshold levels of serum neutralizing antibodies was determined 12 months after the vaccination, and it was 0.62 ± 0.28 and 0.71 ± 0.17 IU/cm3 in foxes and raccoon dogs, respectively, which proves the necessity to perform booster vaccination one year later. No animals vaccinated against rabies with Ferarabivac live vaccine showed any clinical signs of the disease during the entire observation period following the challenge test carried out 30 days post vaccination.

17 September 2025 in Veterinary Science Today
Verified
Journal Article
Open access
PDF file
NLN. N. Lugovskaya
N. N. Lugovskaya
YEYu. S. El’kIna
Yu. S. El’kIna
MSM. A. Shevchenko
M. A. Shevchenko
YGY. M. Gochmuradov
Y. M. Gochmuradov
NKN. D. Klyukina
N. D. Klyukina
ЮЕЮ. С. Елькина
Ю. С. Елькина
Introduction. Foot-and-mouth disease (FMD) is a highly contagious, economically significant disease of cloven-hoofed animals, characterized by vesicular symptoms. There are seven known foot-and-mouth disease virus (FMDV) serotypes (A, O, C, SAT 1, SAT 2, SAT 3 and Asia 1), which immunologically differ from each other. Special attention has been recently paid to FMDV of SAT2/XIV topotype (South African Territories 2) due to its rapid spread. One of the key methods of FMD control is vaccination and assessment of the susceptible animal immune status.Objective. Development and testing of an enzyme-linked immunosorbent assay (ELISA) system based on the indirect liquid-phase blocking ELISA for the determination of antibodies to structural proteins of SAT2/XIV FMDV in order to evaluate the effectiveness of an FMD vaccine based on SAT-2/XIV/2023 FMDV antigen in the process of its production and subsequent use.Materials and methods. The test material included experimental serum samples collected from cattle, pigs and white mice. The developed ELISA test system for assessing the level of post-vaccination antibodies against SAT2/XIV FMDV was validated through comparative testing with commercial test-kits: Test-kit for the determination of SAT 2 FMDV antibodies (Federal Centre for Animal Health, Russia) and “Solid-phase competitive ELISA for antibodies specific to FMDV serotype SAT 2”(IZSLER & The Pirbright Institute, Italy/Great Britain).Results. The effectiveness of the proposed test system in detecting the induction of antibodies against SAT2/XIV FMDV was higher than that of other ELISA systems with the pronounced topotype specificity to the SAT2/VII FMD agent. Specific antibodies were detected in individual cattle on day 7 post vaccination. High diagnostic sensitivity (90%), specificity (98%) and accuracy (95%) ensured high degree of the ELISA results consistency with the known diagnostic status of the tested animals (k-criterion – 0.896).Conclusion. Thus, the ELISA system for assessing humoral immunity against SAT2/XIV FMDV, which is 100% homologous with the vaccine strain and demonstrates high diagnostic parameters, is a reliable tool for assessing the quality of the SAT2/XIV FMD vaccine.

1 January 2022 in Veterinary Science Today
Verified
Journal Article
Closed access
MGM. N. Guseva
M. N. Guseva
MDM. I. Doronin
M. I. Doronin
MSM. A. Shevchenko
M. A. Shevchenko
DMD. V. Mikhalishin
D. V. Mikhalishin
YGY. M. Gochmuradov
Y. M. Gochmuradov
YEYu. S. El'Kina
Yu. S. El'Kina